Frost & Sullivan

OCTOBER 1, 2024

It has established itself as a leading LIMS provider globally and was recognized as the highest-ranking LIMS vendor in growth and innovation in Frost & Sullivan’s first Frost Radar™ report for LIMS in 2023 and 2024. LabVantage LIMS is an enterprise platform serving the full product life cycle.

Life science 104

Life science Biotechnology Consumer packaged goods Strategic partnership 104

Frost & Sullivan

NOVEMBER 30, 2023

SAN ANTONIO – November 30, 2023 – Frost & Sullivan recently researched the contract development and manufacturing organization industry and, based on its findings, recognizes Bushu Pharma with the 2023 Japan Customer Value Leadership Award.

Biotechnology 52

Biotechnology Life science Collaboration 52

Frost & Sullivan

AUGUST 29, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. increase from 2022. However, the pharma/biopharma industry overall shows stagnant R&D activity. Total R&D expenditure is approximately $276.81

Biopharma 52

Biopharma Biotechnology Contract research organization Utilities 52

Frost & Sullivan

JANUARY 17, 2023

17, 2023– The agricultural industry’s ongoing changes—rapid climate change and biodiversity loss—have created a lucrative growth opportunity for agrochemical technology developers. San Antonio – Jan.

Biotechnology 52

Biotechnology Strategic partnership Government Collaboration 52

Frost & Sullivan

APRIL 25, 2023

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. federal government and a wide range of biotechnology, pharmaceutical and medical device companies throughout the world.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52

Frost & Sullivan

MARCH 28, 2025

The pharmaceutical and biotechnology industries are at the cusp of a transformative era in 2025, driven by cutting-edge innovation, evolving regulations, and increasing market pressures. Between 2017 and 2023, the US RLT market saw over 550% growth in total venture capital deals. The market for RLT is set for exponential growth.

Biotech 52

Biotech Biotechnology Strategic partnership Insurance 52

Frost & Sullivan

JANUARY 23, 2025

While 2024 saw a 41% decline in aggregate deal value , falling from $222 billion in 2023 to $130 billion, 2025 is poised for a rebound. Cross-Industry Collaborations Enabling Advanced Research Technological innovation and implementation, especially in AI-driven drug discovery and adaptive clinical trials , was a focal point of the conference.

Biotechnology 52

Biotechnology Mergers and acquisition activities Biotech Biopharma 52